The biotech sector has steadily enjoyed an increase this year, in part thanks to significant advancements and in spite of the uncertainty from the White House as the proposal of a new healthcare bill holds the grip of most life science markets.
The world’s pharmaceutical industry is dominated by the American and European markets. According to Forbes top companies of 2017, the 10 biggest drug companies are all located in these two regions.
Neovasc, Adaptimmune, Curis, Vericel and MannKind top the NASDAQ biotech stock list.
Cancer Genetics acquired a business that will help them expand their oncology offerings and mark in this sector.
Delcath Systems, MannKind, Zogenix, BioLife Solutions and BioDelivery Sciences top the NASDAQ biotech stock list.
Pharmaceutical companies work towards achieving the goal of bringing new cures or treatments to the market and improve the treatment available for patients.
Cogentix Medical, Molecular Templates, Celldex Therapeutics, Cerus and Kura Oncology top the NASDAQ biotech stock list.
As medical devices get technological advancements placing them into networks, the danger of threats to these crucial devices is growing as well. A new piece of legislation in the US Senate seeks to add mandated tests and better protections for remote access points.
Achieve Life Sciences completed its merger with OncoGenex Pharmaceuticals.